Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1667
    +0.0010 (+0.09%)
     

  • GBP/USD

    1.2480
    -0.0031 (-0.25%)
     

  • Bitcoin GBP

    51,028.55
    -386.11 (-0.75%)
     

  • CMC Crypto 200

    1,322.05
    -74.49 (-5.34%)
     

  • S&P 500

    5,103.65
    +55.23 (+1.09%)
     

  • DOW

    38,247.24
    +161.44 (+0.42%)
     

  • CRUDE OIL

    84.07
    +0.50 (+0.60%)
     

  • GOLD FUTURES

    2,350.20
    +7.70 (+0.33%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

U.S. FDA warns on newer class of type 2 diabetes drugs

Reuters - UK Focus

May 15 (Reuters) - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drug sold by AstraZeneca (NYSE: AZN - news) , Johnson & Johnson (NYSE: JNJ - news) and Eli Lilly in partnership with Boehringer Ingleheim may a cause dangerously high levels of blood acids that could require hospitalization.

The drugs belong to a class known as SGLT2 inhibitors that work by causing blood sugar to be secreted in the urine. They include AstraZeneca's Farxiga (dapagliflozin), J&J's Invokana (canagliflozin) and Jardiance (embagliflozin) from Lilly and Boehringer.

The FDA in a warning on its website said the medicines may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones. (Reporting by Bill Berkrot; Editing by Jeffrey Benkoe)